ClinicalTrials.gov
public full text
Public Domain
Observational Study of Kibow Biotics in Chronic Kidney Failure Patients on Dialysis
A specifically formulated probiotic product comprised of defined and tested microbial strains may afford renoprotection in what has been generally called "Enteric DialysisTM". However, it is also referred to as enteric toxin reduction technology. Our hypothesis is to assess the potential benefits in devising a bowel-based probiotic formulation (Kibow® Biotics/RenadylTM) as a dietary supplement product for patients undergoing dialysis along with standardized care of treatment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Pilot-Scale Clinical Trials of Kibow Biotics® in Chronic Kidney Failure#900032
- Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis#887722
- Probiotic Supplements in Chronic Kidney Disease#810067
- Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial#801104
- Supporting the Improvement and Management of Prescribing for Urinary Tract Infections (SIMPle)#217070
Record · ID 830953
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive